BDTX Stock Price, Black Diamond Therapeutics Quote, Chart

Market Summary

USD4.87-0.37

Delayed

-7.06%

BDTX Stock Price

View Fullscreen

BDTX RSI Chart

BDTX Valuation

Market Cap

274.0M

Price/Earnings (Trailing)

-3.43

Price/Sales (Trailing)

142.39

Price/Free Cashflow

-4.03

BDTX Price/Sales (Trailing)

BDTX Profitability

Return on Equity

-76.5%

Return on Assets

-55.99%

Free Cashflow Yield

-24.79%

BDTX Fundamentals

BDTX Revenue

Revenue (TTM)

1.9M

Rev. Growth (Yr)

2.41%

Rev. Growth (Qtr)

1.19%

BDTX Earnings

Earnings (TTM)

-79.8M

Earnings Growth (Yr)

12.69%

Earnings Growth (Qtr)

6.1%

Breaking Down BDTX Revenue

Last 7 days

-20.3%

Last 30 days

-14.6%

Last 90 days

-9.0%

Trailing 12 Months

200.6%

How does BDTX drawdown profile look like?

BDTX Financial Health

Current Ratio

7.05

BDTX Investor Care

Shares Dilution (1Y)

54.06%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.3M	0	0	1.9M
2022	2.7M	0	2.3M	2.2M
2021	4.4M	4.5M	4.1M	3.5M
2020	1.2M	2.1M	3.2M	4.0M
2019	0	0	0	461.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Black Diamond Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	behbahani ali	acquired	14,373	4.54	3,166	-
Mar 15, 2024	dixon wendy l	acquired	14,768	4.54	3,253	-
Dec 15, 2023	behbahani ali	acquired	12,162	2.73	4,455	-
Dec 15, 2023	dixon wendy l	acquired	11,037	2.73	4,043	-
Oct 17, 2023	biotech growth n v	bought	934,080	2.3352	400,000	-
Sep 15, 2023	velleca mark a.	acquired	18,748	3.6	5,208	president & ceo
Sep 15, 2023	behbahani ali	acquired	11,876	3.6	3,299	-
Sep 15, 2023	dixon wendy l	acquired	10,749	3.6	2,986	-
Jul 05, 2023	ra capital management, l.p.	bought	4,679,250	5.00	935,850	-
Jul 05, 2023	behbahani ali	bought	5,000,000	5.00	1,000,000	-

Which funds bought or sold BDTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Beacon Capital Management, LLC	unchanged	-	34,353	79,168	0.02%
May 16, 2024	JANE STREET GROUP, LLC	added	353	1,115,000	1,270,310	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	7,968,200	17,875,600	0.23%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	new	-	1,302,990	1,302,990	0.09%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-2.51	783,291	1,815,380	-%
May 15, 2024	AE Wealth Management LLC	sold off	-100	-46,168	-	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	added	225	13,668	16,478	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-197,765	-	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-11.09	3,061,230	8,128,220	0.85%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-6.41	199,092	488,241	-%

Are Funds Buying or Selling BDTX?

Are funds buying BDTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BDTX

No. of Funds

Unveiling Black Diamond Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	new enterprise associates 16, l.p.	7.9%	4,448,757	SC 13D/A
May 09, 2024	ra capital management, l.p.	4.95%	2,788,028	SC 13D/A
Mar 11, 2024	t. rowe price investment management, inc.	12.9%	6,675,756	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	7.6%	3,927,879	SC 13G
Feb 13, 2024	bb biotech ag	16.5%	8,517,839	SC 13G/A
Nov 09, 2023	versant venture capital vi, l.p.	7.7%	3,947,941	SC 13D/A
Feb 14, 2023	bb biotech ag	14.8%	5,377,839	SC 13G/A
Jul 08, 2022	blackrock inc.	3.5%	1,272,112	SC 13G
Apr 14, 2022	bb biotech ag	11.0%	3,988,402	SC 13G/A
Feb 11, 2022	bb biotech ag	9.5%	3,440,000	SC 13G/A

Recent SEC filings of Black Diamond Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	SC 13D/A	13D - Major Acquisition
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 12, 2024	3	Insider Trading
Apr 12, 2024	3	Insider Trading
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Black Diamond Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Black Diamond Therapeutics Inc News

Latest updates

Black Diamond Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	1.2%	637	630	622	677	562	406	588	776	948	1,152	1,254	1,162	881	744	440	1.00	9.00	11.00
Operating Expenses	-2.9%	20,246	20,855	21,561	21,852	22,124	25,679	26,080	35,364	34,715	30,713	23,183	18,480	15,028	12,879	10,344	8,148	6,999	3,841
S&GA Expenses	-100.0%	-	5,566	6,808	7,243	6,277	7,893	6,416	7,738	7,996	7,893	5,427	5,551	4,858	5,525	2,884	2,514	1,353	828
R&D Expenses	-11.4%	13,545	15,289	14,753	14,609	15,847	17,786	19,664	27,626	26,719	22,820	17,756	12,929	10,170	7,354	7,460	5,634	5,646	3,013
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	-	-	-	-	-
Net Income	6.1%	-18,225	-19,408	-20,875	-21,078	-21,654	-25,507	-25,867	-35,077	-34,351	-30,301	-22,626	-17,912	-14,571	-12,145	-9,875	-9,268	-12,287	-3,828
Net Income Margin	3.2%	-41.47*	-42.85*	-38.17*	-40.83*	-41.15*	-44.45*	-36.26*	-29.63*	-23.29*	-	-	-	-	-	-	-	-	-
Free Cashflow	-51.9%	-21,199	-13,956	-20,031	-21,939	-16,468	-28,607	-24,379	-27,971	-26,013	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-10.1%	143	159	172	120	136	156	180	199	219	248	274	288	313	330	346	349	363	158	52.00
Current Assets	-11.4%	119	134	147	93.00	108	128	151	169	188	216	242	271	297	320	336	208	362	156	52.00
Cash Equivalents	-53.3%	26.00	56.00	58.00	42.00	39.00	34.00	54.00	56.00	54.00	67.00	47.00	37.00	14.00	36.00	56.00	64.00	357	155	52.00
Net PPE	-5.0%	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.6%	38.00	42.00	38.00	38.00	37.00	41.00	47.00	46.00	47.00	52.00	55.00	37.00	33.00	22.00	19.00	6.00	8.00	5.00	7.00
Current Liabilities	-14.2%	17.00	20.00	15.00	14.00	13.00	15.00	21.00	20.00	19.00	24.00	26.00	23.00	19.00	14.00	11.00	6.00	7.00	5.00	3.00
Shareholder's Equity	-10.6%	104	117	134	82.00	98.00	116	133	152	173	196	219	251	281	308	327	343	355	-	-
Retained Earnings	-4.4%	-435	-417	-398	-375	-355	-334	-313	-292	-269	-243	-217	-182	-148	-118	-95.60	-77.69	-63.11	-50.97	-15.71
Additional Paid-In Capital	1.1%	540	534	533	458	455	453	450	447	444	440	437	434	429	425	422	420	418	4.00	0.00
Shares Outstanding	1.7%	53.00	52.00	52.00	37.00	37.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	-	-	-	-	-	-	-
Float	-	-	-	-	115	-	-	-	55.00	-	-	-	340	-	-	-	1,010	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-51.9%	-21,199	-13,956	-18,362	-14,368	-20,031	-21,939	-16,476	-18,067	-28,600	-24,046	-26,482	-25,165	-24,455	-15,774	-11,486	-13,567	-11,319	-7,486	-5,310	-5,000	-6,878
Share Based Compensation	11.5%	1,713	1,536	2,751	2,646	2,671	2,906	2,664	3,252	3,375	3,376	3,009	4,558	3,094	2,470	1,999	1,419	1,877	2,510	850	192	91.00
Cashflow From Investing	-212.1%	-13,734	12,249	-37,884	17,175	24,806	2,322	14,507	19,808	16,729	43,242	35,697	48,200	3,474	-6,648	4,597	-279,640	-	-2.00	-11.00	2.00	-10.00
Cashflow From Financing	9078.3%	4,130	-46.00	71,927	-	51.00	-28.00	52.00	-	153	-	64.00	184	481	830	270	-	213,844	83,495	44,331	-70.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BDTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,545	$ 14,753
General and administrative	6,701	6,808
Total operating expenses	20,246	21,561
Loss from operations	(20,246)	(21,561)
Other income (expense):
Interest income	637	622
Other income (expense)	1,384	64
Total other income (expense), net	2,021	686
Net loss	$ (18,225)	$ (20,875)
Net loss per share, basic (in dollars per share)	$ (0.35)	$ (0.57)
Net loss per share, diluted (in dollars per share)	$ (0.35)	$ (0.57)
Weighted average common shares outstanding, basic (in shares)	51,808,849	36,483,878
Weighted average common shares outstanding, diluted (in shares)	51,808,849	36,483,878
Comprehensive loss:
Net loss	$ (18,225)	$ (20,875)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	(68)	648
Comprehensive loss	$ (18,293)	$ (20,227)

BDTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,422	$ 56,221
Investments	89,777	75,179
Prepaid expenses and other current assets	3,607	2,634
Total current assets	118,806	134,034
Property and equipment, net	1,644	1,730
Restricted cash	819	823
Right-of-use assets	21,252	21,980
Total assets	142,521	158,567
Current liabilities:
Accounts payable	1,176	2,324
Accrued expenses and other current liabilities	15,678	17,322
Total current liabilities	16,854	19,646
Non-current operating lease liabilities	21,361	22,185
Total liabilities	38,215	41,831
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023	7	7
Additional paid-in capital	540,050	534,187
Accumulated other comprehensive loss	(95)	(27)
Accumulated deficit	(435,656)	(417,431)
Total stockholders' equity	104,306	116,736
Total liabilities and stockholders' equity	$ 142,521	$ 158,567

About Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. David M. Epstein Ph.D.
WEBSITE	blackdiamondtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	65

Black Diamond Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Black Diamond Therapeutics Inc? What does BDTX stand for in stocks?

BDTX is the stock ticker symbol of Black Diamond Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Black Diamond Therapeutics Inc (BDTX)?

As of Fri May 17 2024, market cap of Black Diamond Therapeutics Inc is 273.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDTX stock?

You can check BDTX's fair value in chart for subscribers.

What is the fair value of BDTX stock?

You can check BDTX's fair value in chart for subscribers. The fair value of Black Diamond Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Black Diamond Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BDTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Black Diamond Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BDTX is over valued or under valued. Whether Black Diamond Therapeutics Inc is cheap or expensive depends on the assumptions which impact Black Diamond Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDTX.

What is Black Diamond Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BDTX's PE ratio (Price to Earnings) is -3.43 and Price to Sales (PS) ratio is 142.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDTX PE ratio will change depending on the future growth rate expectations of investors.